<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="57311"><DrugName>ramatercept</DrugName><DrugNamesKey><Name id="42985069">ramatercept</Name></DrugNamesKey><DrugSynonyms><Name><Value>ACE-031</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>GDF-8 inhibitor (muscle loss), Acceleron</Value></Name><Name><Value>myostatin inhibitor (muscle loss), Acceleron</Value></Name><Name><Value>ACE-03X</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ActRIIB-IgG1</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HGT-4510</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>ramatercept</Value><Types><Type>USAN</Type><Type>INN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1009646">Acceleron Pharma Inc</CompanyOriginator><CompaniesSecondary><Company id="1009646">Acceleron Pharma Inc</Company><Company id="24652">Shire plc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="57311" type="Drug"><TargetEntity id="474273" type="siDrug">RAP-031</TargetEntity><TargetEntity id="454403" type="siDrug">Ramatercept</TargetEntity></SourceEntity><SourceEntity id="1009646" type="Company"><TargetEntity id="4296015497" type="organizationId">Acceleron Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="24652" type="Company"><TargetEntity id="4295894723" type="organizationId">Shire PLC</TargetEntity></SourceEntity><SourceEntity id="2020" type="ciIndication"><TargetEntity id="10013801" type="MEDDRA"/><TargetEntity id="D020388" type="MeSH"/><TargetEntity id="98896" type="ORPHANET"/><TargetEntity id="-2123687174" type="omicsDisease"/><TargetEntity id="143" type="siCondition"/></SourceEntity><SourceEntity id="2369" type="ciIndication"><TargetEntity id="D56.1" type="ICD10"/><TargetEntity id="282.44" type="ICD9"/><TargetEntity id="10043391" type="MEDDRA"/><TargetEntity id="D017086" type="MeSH"/><TargetEntity id="848" type="ORPHANET"/><TargetEntity id="-1527735319" type="omicsDisease"/><TargetEntity id="2426" type="siCondition"/></SourceEntity><SourceEntity id="3210" type="ciIndication"><TargetEntity id="10063024" type="MEDDRA"/><TargetEntity id="D055948" type="MeSH"/><TargetEntity id="-531960762" type="omicsDisease"/><TargetEntity id="1319" type="siCondition"/></SourceEntity><SourceEntity id="4574" type="Action"><TargetEntity id="3787" type="Mechanism">Activin Receptor Type IIB (ActR-IIB) Inhibitors</TargetEntity><TargetEntity id="4284" type="Mechanism">Anti-Activin Receptor Type-2B (ACVR2B; ACTR-IIB)</TargetEntity></SourceEntity><SourceEntity id="7928" type="Action"><TargetEntity id="2431" type="Mechanism">Anti-GDF8 (Myostatin)</TargetEntity><TargetEntity id="4869" type="Mechanism">Growth/Differentiation Factor 8 (GDF-8; Myostatin) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00052" type="ciTarget"><TargetEntity id="723834212933" type="siTarget">Activin receptor type-2B</TargetEntity><TargetEntity id="7024" type="omicsTarget"/></SourceEntity><SourceEntity id="PTGT-00805" type="ciTarget"><TargetEntity id="82988442526603" type="siTarget">Growth/differentiation factor 8</TargetEntity><TargetEntity id="6071" type="omicsTarget"/></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsSecondary><Indication id="2020">Duchenne dystrophy</Indication><Indication id="2369">Beta thalassemia</Indication><Indication id="3210">Sarcopenia</Indication></IndicationsSecondary><ActionsPrimary><Action id="4574">Activin type-IIB receptor antagonist</Action><Action id="7928">GDF-8 antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="1408">Muscle system agent</Action></ActionsSecondary><Technologies><Technology id="180">Antibody fragment</Technology><Technology id="84">Protein fusion</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="761">Biological therapeutic</Technology></Technologies><LastModificationDate>2017-11-16T11:38:17.000Z</LastModificationDate><ChangeDateLast>2019-02-01T00:00:00.000Z</ChangeDateLast><AddedDate>2007-05-09T10:38:29.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1009646" linkType="Company"&gt;Acceleron&lt;/ulink&gt; was developing  the lead molecule ramatercept (ACE-031; ActRIIB-IgG1; HGT-4510) from a series of  recombinant fusion protein   molecules, produced by combining a portion of the activin receptor type IIb (ActRIIB), that  inhibits myostatin (GDF-8), to a portion of a human antibody (IgG1), for the potential sc treatment of Duchenne Muscular Dystrophy (DMD) and other neuromuscular disorders  [&lt;ulink linkID="1015457" linkType="Reference"&gt;1015457&lt;/ulink&gt;], [&lt;ulink linkID="1129625" linkType="Reference"&gt;1129625&lt;/ulink&gt;], [&lt;ulink linkID="1129741" linkType="Reference"&gt;1129741&lt;/ulink&gt;], [&lt;ulink linkID="1414283" linkType="Reference"&gt;1414283&lt;/ulink&gt;].   In April 2010, a phase II study was initiated in children with DMD [&lt;ulink linkID="1091708" linkType="Reference"&gt;1091708&lt;/ulink&gt;]. By September 2010, it was reported that a phase IIa and a global phase II/III trial were planned [&lt;ulink linkID="1129625" linkType="Reference"&gt;1129625&lt;/ulink&gt;], [&lt;ulink linkID="1129741" linkType="Reference"&gt;1129741&lt;/ulink&gt;]. In February 2011, clinical development was suspended, while preclinical studies were being conducted to evaluate if clinical studies should continue [&lt;ulink linkID="1414283" linkType="Reference"&gt;1414283&lt;/ulink&gt;]. In August 2011, a phase IIa trial was on hold while clinical safety was under review [&lt;ulink linkID="1214547" linkType="Reference"&gt;1214547&lt;/ulink&gt;]. In May 2013, Acceleron and its licensee &lt;ulink linkID="24652" linkType="Company"&gt;Shire&lt;/ulink&gt; decided not to restart the program following additional preclinical studies and the program was presumed to be terminated [&lt;ulink linkID="1414283" linkType="Reference"&gt;1414283&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Shire, in collaboration with Acceleron, was previously developing ramatercept for the potential treatment of DMD  [&lt;ulink linkID="1129625" linkType="Reference"&gt;1129625&lt;/ulink&gt;], [&lt;ulink linkID="1129741" linkType="Reference"&gt;1129741&lt;/ulink&gt;]. In April 2013, the company discontinued the development  and returned its rights to Acceleron [&lt;ulink linkID="1414035" linkType="Reference"&gt;1414035&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In March 2013, ramatercept received FDA Orphan Drug status for   beta-thalassemia [&lt;ulink linkID="1394081" linkType="Reference"&gt;1394081&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2010, the FDA granted ramatercept Fast Track status for DMD [&lt;ulink linkID="1121347" linkType="Reference"&gt;1121347&lt;/ulink&gt;]. At that time, ramatercept also received Orphan Drug status from the  FDA for DMD [&lt;ulink linkID="1125161" linkType="Reference"&gt;1125161&lt;/ulink&gt;]; by February 2012, Orphan Drug status was also granted in the EU [&lt;ulink linkID="1267718" linkType="Reference"&gt;1267718&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In April 2010, a randomized, double-blind, placebo-controlled, dose-ranging, phase II study (&lt;ulink linkID="65390" linkType="Protocol"&gt;NCT01099761&lt;/ulink&gt;, A031-03) was initiated in Canada in children with DMD receiving concurrent corticosteroid therapy (expected n = 76)  to evaluate the safety, tolerability and pharmacokinetics of ramatercept. The study was expected to complete in February 2012 [&lt;ulink linkID="1091708" linkType="Reference"&gt;1091708&lt;/ulink&gt;], [&lt;ulink linkID="1096197" linkType="Reference"&gt;1096197&lt;/ulink&gt;]. By January 2011, an extension study (&lt;ulink linkID="72179" linkType="Protocol"&gt;NCT01239758&lt;/ulink&gt;, A031-06) had also been initiated, whereby patient enrollment was by invitation only [&lt;ulink linkID="1159460" linkType="Reference"&gt;1159460&lt;/ulink&gt;]. In April 2012, data from this study were reported at the 64th AAN meeting in New Orleans, LA. The drug was well tolerated and no serious or severe adverse events as well as significant changes in laboratory results were observed [&lt;ulink linkID="1283010" linkType="Reference"&gt;1283010&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In August  2009, a  randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic,Canadian phase Ib study (&lt;ulink linkID="59374" linkType="Protocol"&gt;NCT00952887&lt;/ulink&gt;; A031-02)  was initiated in healthy postmenopausal women (expected n= 80). At that time, the trial was expected to be completed in February 2011 [&lt;ulink linkID="1139411" linkType="Reference"&gt;1139411&lt;/ulink&gt;], [&lt;ulink linkID="1038934" linkType="Reference"&gt;1038934&lt;/ulink&gt;]. In October 2010, preliminary results from the phase Ib trial were presented at the 15th International Congress of the World Muscle Society in Kumamoto, Japan.  Results from 60 subjects showed that the drug was well-tolerated at all dose levels with a half-life of 12 days. The rug increased the mean total body lean mass by 5.2% and thigh muscle volume by 4.1%. Bone formation and fat mass biomarkers were  also improved and decrease in bone resorption biomarker levels was also reported [&lt;ulink linkID="1139225" linkType="Reference"&gt;1139225&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2008, a randomized, double-blind, placebo-controlled, single-dose, dose-escalation, Canadian phase I trial (&lt;ulink linkID="38516" linkType="Protocol"&gt;NCT00755638&lt;/ulink&gt;; A031-01) began. The study would evaluate the safety and tolerability of single, escalating sc doses of ramatercept in healthy postmenopausal volunteers (expected n = 48). The trial was expected to complete in April 2009. At that time, the study was ongoing but no longer recruiting  [&lt;ulink linkID="945126" linkType="Reference"&gt;945126&lt;/ulink&gt;], [&lt;ulink linkID="953758" linkType="Reference"&gt;953758&lt;/ulink&gt;]. In September 2009, preliminary results were reported. Data showed ramatercept was safe and well-tolerated. Patients received 1 or 3 mg/kg doses of ramatercept. The drug   increased lean body mass and muscle volume in a dose-dependent manner  as well as   bone formulation biomarker levels. The  biomarkers of fat mass were  also improved [&lt;ulink linkID="1038934" linkType="Reference"&gt;1038934&lt;/ulink&gt;]. Later in September 2009, further  preliminary data  were presented at the 14th International Congress of the World Muscle Society in Geneva, Switzerland.    Patients receiving the drug experienced greater increases in both lean body mass and muscle volume compared with placebo.  Ramatercept had a linear pharmacokinetic profile with a half-life of 10 to 15 days    [&lt;ulink linkID="1040851" linkType="Reference"&gt;1040851&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In May  2007, IND enabling activities were underway [&lt;ulink linkID="792267" linkType="Reference"&gt;792267&lt;/ulink&gt;]. By September 2007, the  phase I trial was expected to begin in early 2008 [&lt;ulink linkID="831606" linkType="Reference"&gt;831606&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;in February 2012, additional preclinical toxicology studies were to be conducted in 2012 [&lt;ulink linkID="1267718" linkType="Reference"&gt;1267718&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2008, preclinical data were presented at the 38th SFN annual meeting in Washington DC, showing that ActRIIB.mFc, ActRIIB conjugated with a mouse Fc Domain, reduced weakness and increased weight in a mouse model of amyotrophic lateral sclerosis [&lt;ulink linkID="954339" linkType="Reference"&gt;954339&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2007, ramatercept had been shown to increase skeletal muscle mass and strength in models of amyotrophic lateral sclerosis (ALS), sarcopenia, muscular dystrophy and diet-induced obesity; the effect was potent and specific [&lt;ulink linkID="792267" linkType="Reference"&gt;792267&lt;/ulink&gt;], [&lt;ulink linkID="792265" linkType="Reference"&gt;792265&lt;/ulink&gt;]. Similar data from mouse studies were presented at the Gordon Research Conference on Myogenesis in Lucca, Italy, in May 2007 [&lt;ulink linkID="794262" linkType="Reference"&gt;794262&lt;/ulink&gt;]. Further data from a preclinical mouse study of glucocorticoid-induced muscle loss was reported in October 2007 at the 12th International Congress of the World Muscle Society in Sicily, Italy. Treatment with ramatercept resulted in a 19% increase in lean body mass, while a 5% reduction in lean body mass and weight loss was seen in animals treated with dexamethasone. Ramatercept, in combination with dexamethasone, resulted in an 11% increase in lean body mass demonstrating the drug's ability to offset the muscle loss associated with glucocorticoid treatment [&lt;ulink linkID="840940" linkType="Reference"&gt;840940&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2006, preclinical investigations into compounds for the treatment of muscle wasting diseases was underway [&lt;ulink linkID="667869" linkType="Reference"&gt;667869&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="24652">Shire plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2013-05-02T00:00:00.000Z</StatusDate><Source id="1414283" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3210">Sarcopenia</Indication><StatusDate>2013-05-02T00:00:00.000Z</StatusDate><Source id="1414283" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2013-05-02T00:00:00.000Z</StatusDate><Source id="1414283" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2369">Beta thalassemia</Indication><StatusDate>2013-05-02T00:00:00.000Z</StatusDate><Source id="1414283" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="24652">Shire plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2010-09-09T00:00:00.000Z</StatusDate><Source id="1129741" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate>2010-04-02T00:00:00.000Z</StatusDate><Source id="1091708" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2010-04-02T00:00:00.000Z</StatusDate><Source id="1091708" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2369">Beta thalassemia</Indication><StatusDate>2013-03-11T00:00:00.000Z</StatusDate><Source id="1394081" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24652">Shire plc</Company><Country id="GB">UK</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2011-02-28T00:00:00.000Z</StatusDate><Source id="1414283" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate>2011-02-28T00:00:00.000Z</StatusDate><Source id="1414283" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="2020">Duchenne dystrophy</Indication><StatusDate>2011-02-28T00:00:00.000Z</StatusDate><Source id="1414283" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="2369">Beta thalassemia</Indication><StatusDate>2011-02-28T00:00:00.000Z</StatusDate><Source id="1414283" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate>2006-05-16T00:00:00.000Z</StatusDate><Source id="667869" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1009646">Acceleron Pharma Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3210">Sarcopenia</Indication><StatusDate>2008-09-17T00:00:00.000Z</StatusDate><Source id="945126" type="TRIALREG"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1009646">Acceleron Pharma Inc</OwnerCompany><Country id="US">US</Country><Indication id="2020">Duchenne dystrophy</Indication><AwardedIndication>Treatment of Duchenne Muscular Dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-08-04T00:00:00.000Z</MileStoneDate><Source id="1121347" type="PR"/></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1009646">Acceleron Pharma Inc</OwnerCompany><Country id="US">US</Country><Indication id="2020">Duchenne dystrophy</Indication><AwardedIndication>Treatment of Duchenne muscular dystrophy</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2010-08-16T00:00:00.000Z</MileStoneDate><Source id="1125161" type="PR"/></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00052"><Name>Activin type-IIB receptor</Name><SwissprotNumbers><Swissprot>P27040</Swissprot><Swissprot>P27041</Swissprot><Swissprot>P38445</Swissprot><Swissprot>Q13705</Swissprot><Swissprot>Q95126</Swissprot></SwissprotNumbers></Target><Target id="PTGT-00805"><Name>GDF-8</Name><SwissprotNumbers><Swissprot>O08689</Swissprot><Swissprot>O14793</Swissprot><Swissprot>O18828</Swissprot><Swissprot>O18830</Swissprot><Swissprot>O18831</Swissprot><Swissprot>O18836</Swissprot><Swissprot>O35312</Swissprot><Swissprot>O42220</Swissprot><Swissprot>O42221</Swissprot><Swissprot>O42222</Swissprot><Swissprot>Q5RZV4</Swissprot><Swissprot>Q5USV5</Swissprot><Swissprot>Q5USV6</Swissprot><Swissprot>Q5USV7</Swissprot><Swissprot>Q5USV8</Swissprot><Swissprot>Q5USV9</Swissprot><Swissprot>Q5USW0</Swissprot><Swissprot>Q5USW1</Swissprot><Swissprot>Q6DTL9</Swissprot><Swissprot>Q6J1J2</Swissprot><Swissprot>Q6T5B8</Swissprot><Swissprot>Q6UKZ8</Swissprot><Swissprot>Q6X5V1</Swissprot><Swissprot>Q8HY52</Swissprot><Swissprot>Q95J86</Swissprot><Swissprot>Q9GM97</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1009646">Acceleron Pharma Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>3</CountTotal></Company><Company><Company id="1045019">Muscular Dystrophy Association</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14166">The Salk Institute for Biological Studies</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20300">Takeda Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>0</CountActive><CountInactive>1</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="131879" title="Shire and Acceleron to codevelop ACE-031 and other ActRIIB molecules for Duchenne Muscular Dystrophy Worldwide excluding North America   "/><Deal id="133514" title="Acceleron to receive funding from the MDA to develop its ACE-031 for DMD "/><Deal id="178403" title="Acceleron Pharma to use IP from Salk Institute related to type IIB activin receptors to develop products for therapeutic and diagnostic purposes"/></Deals><PatentFamilies><PatentFamily id="1111758" number="WO-2011056896" title="Methods for treating fatty liver disease"/><PatentFamily id="1116141" number="WO-2009158025" title="Methods for dosing an ActRIIb antagonist and monitoring of treated patients"/><PatentFamily id="1288775" number="WO-2011031901" title="ActRIIb antagonists and dosing and uses thereof"/><PatentFamily id="1590068" number="WO-2008073351" title="Uses of cerberus, coco and derivatives thereof"/><PatentFamily id="1767176" number="WO-2010144452" title="Methods for increasing thermogenic adipocytes"/><PatentFamily id="2054687" number="WO-2005115439" title="Cerberus/Coco derivatives and uses thereof"/><PatentFamily id="2081879" number="WO-2012092299" title="Therapeutic and diagnostic methods involving biglycan and utrophin"/><PatentFamily id="2254583" number="WO-2007006025" title="Lefty, lefty derivatives and uses therof"/><PatentFamily id="2475820" number="WO-2009158015" title="Antagonists of ActRIIb and uses for increasing red blood cell levels"/><PatentFamily id="2517890" number="WO-2013059347" title="Methods and compositions for treating ineffective erythropoiesis"/><PatentFamily id="2519140" number="WO-2013063536" title="ActRIIB binding agents and uses thereof"/><PatentFamily id="2542787" number="WO-2008097541" title="Variants derived from ActRIIB and uses therefor."/><PatentFamily id="3055767" number="WO-2015161220" title="Methods for increasing red blood cell levels and treating sickle-cell disease"/><PatentFamily id="3304106" number="WO-2008076437" title="Activin-ActRII antagonists and uses for increasing red blood cell levels."/><PatentFamily id="3444968" number="WO-2016183280" title="Treatment of beta-thalassemia using ActRII ligand traps"/><PatentFamily id="3497612" number="WO-2015192111" title="Methods and compositions for treating ulcers"/><PatentFamily id="3690545" number="WO-2016090077" title="Activin-ActRII antagonists and uses for treating anemia"/><PatentFamily id="4190699" number="WO-2018162931" title="Method relating to myostatin pathway inhibition"/><PatentFamily id="656190" number="WO-2005084699" title="ALK7 and myostatin inhibitors and uses thereof"/><PatentFamily id="750899" number="WO-2011063018" title="ActRIIb proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy"/><PatentFamily id="863468" number="WO-2006012627" title="ActRII receptor polypeptides, methods and compositions"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>8</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>10</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Acceleron Pharma Inc" id="1009646"/><CountAsOwner>19</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>19</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Royal Marsden NHS Trust" id="1010270"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Enlight Biosciences" id="1040723"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="The Insitute of Cancer Research" id="1125142"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alkermes plc" id="14005"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Celgene Corp" id="15331"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Takeda Pharmaceutical Co Ltd" id="20300"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Brown University" id="20545"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of London" id="20607"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>